stoxline Quote Chart Rank Option Currency Glossary
  
Daxor Corporation (DXR)
9.55  0.17 (1.81%)    05-17 16:00
Open: 9.5
High: 9.9599
Volume: 720
  
Pre. Close: 9.38
Low: 9.5
Market Cap: 45(M)
Technical analysis
2024-05-17 4:45:12 PM
Short term     
Mid term     
Targets 6-month :  11.67 1-year :  13.64
Resists First :  9.99 Second :  11.67
Pivot price 9.69
Supports First :  9.41 Second :  9.05
MAs MA(5) :  9.54 MA(20) :  9.69
MA(100) :  8.95 MA(250) :  9.13
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  30.5 D(3) :  25.9
RSI RSI(14): 51.2
52-week High :  13.13 Low :  7.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DXR ] has closed above bottom band by 25.3%. Bollinger Bands are 61.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.97 - 10.04 10.04 - 10.09
Low: 9.37 - 9.44 9.44 - 9.5
Close: 9.46 - 9.57 9.57 - 9.65
Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Headline News

Fri, 17 May 2024
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript - MSN

Fri, 17 May 2024
(DXR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Sun, 12 May 2024
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn Patients - Yahoo Singapore News

Mon, 01 Apr 2024
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 - Yahoo Canada Finance

Mon, 25 Mar 2024
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance ... - GlobeNewswire

Thu, 04 Jan 2024
DXR Stock Quote Price and Forecast - CNN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 5 (M)
Shares Float 2 (M)
Held by Insiders 57 (%)
Held by Institutions 1.7 (%)
Shares Short 9 (K)
Shares Short P.Month 7 (K)
Stock Financials
EPS 0.14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.07
Profit Margin 171.7 %
Operating Margin -511.4 %
Return on Assets (ttm) -1.6 %
Return on Equity (ttm) 0.8 %
Qtrly Rev. Growth -14.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.03
EBITDA (p.s.) 0
Qtrly Earnings Growth -57.6 %
Operating Cash Flow -4 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 68.21
PEG Ratio 0
Price to Book value 1.34
Price to Sales 281.08
Price to Cash Flow -12.56
Stock Dividends
Dividend 0.02
Forward Dividend 0
Dividend Yield 0.3%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android